Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. The public reports of this drug’s clinical benefits were thrilling to everyone – patients, physicians, and researchers. But we have not been the only people on this mission.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Our ambition is to develop life-changing treatments for patients. Source link.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. Lead Pharma may receive payments of up to €260 million plus royalties on sales.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Broad Institute

OCTOBER 4, 2023

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

Alta Sciences

JULY 28, 2023

Miniature Swine: Changing the Bias for Nonclinical Studies on Small Molecules and Biologics pmjackson Fri, 07/28/2023 - 16:07 Miniature swine have been widely used for research studies since the 1960s—most commonly within the scope of dermal testing due to similarities of their integument to humans.

Small Molecule 52

Small Molecule Pharmaceutical Companies Research FDA 52

Alta Sciences

JULY 28, 2023

Miniature Swine: Changing the Bias for Nonclinical Studies on Small Molecules and Biologics pmjackson Fri, 07/28/2023 - 16:07 Miniature swine have been widely used for research studies since the 1960s—most commonly within the scope of dermal testing due to similarities of their integument to humans.

Small Molecule 52

Small Molecule Pharmaceutical Companies Research FDA 52

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

Broad Institute

OCTOBER 29, 2024

Related groups Center for the Development of Therapeutics (CDoT) A team of researchers at Broad Institute of MIT and Harvard, in a long-term project that has included industry collaborators at Bayer and Trueline Therapeutics, has developed a compound called BRD-810 that holds promise as a therapeutic candidate for cancer.

Drugs 133

Drugs Small Molecule Pharmacokinetics Clinical Trials 133

Drug Target Review

JULY 23, 2024

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. At the time, research and leadership roles in biotech/pharma industry were predominately held by men and there were not as many opportunities for career development and mentorship from women leaders.

Small Molecule 115

Small Molecule Targeted Protein Degradation Science Disease 115

Broad Institute

SEPTEMBER 23, 2024

Working toward a systematic method of optimizing mRNA drugs for specific uses, researchers at the Broad Institute of MIT and Harvard and the Massachusetts Institute of Technology have developed an approach for tailoring mRNAs to produce a greater abundance of protein, or to produce protein for a longer period of time, compared to native mRNA.

RNA 133

RNA Vaccine Small Molecule Therapies 133

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Many cell lines used in pancreatic cancer research, for example, are generally not genetically aligned with most patients in the clinic.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Target Review

OCTOBER 6, 2023

This interview explores how CoRegen’s innovative techniques are not only transforming cancer treatment but also hold promise for a wide range of medical applications, all while minimising the side effects often associated with traditional therapies. For what indications can this approach be used?

Small Molecule 111

Small Molecule Engineering Protein Expression Therapies 111

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 83

Small Molecule Drugs Clinical Trials Therapies 83

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

NOVEMBER 25, 2024

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. This suited my personality and constant curiosity more than academic research.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Clinical Research Immune Response 52

Drug Target Review

SEPTEMBER 25, 2024

4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

ASPET

DECEMBER 21, 2023

Our previous research showed that the novel and low-toxicity peptide DR3penA had a strong antifibrotic effect on a bleomycin-induced murine model. The peptide DR3penA can be further developed for the treatment of multiple fibrotic lung diseases.

Biochemical Assays 100

Biochemical Assays Small Molecule Disease Regulations 100

Chemical Biology and Drug Design

MAY 11, 2023

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hyperlipidemia. In discovery of novel small molecules that interfere PCSK9/LDLR protein–protein interaction (PPI), structural modification was performed based on our previously derived compounds.

Small Molecule 100

Small Molecule Treatment Research 100

Chemical Biology and Drug Design

JUNE 7, 2023

Our MD simulation results also revealed that the 5-hydroxy-4H-thioxen-4-one group and terminal carboxyl group were critical groups responsible for interaction of small molecules with SIRT7. In our study, we demonstrated that targeting SIRT7 may offer novel therapeutic options for cancer treatment.

Small Molecule 100

Small Molecule Treatment Research 100

Drug Target Review

JULY 13, 2023

Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

KIF1A

JANUARY 27, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. #ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community.

Therapies 111

Therapies Small Molecule DNA Treatment 111

Chemical Biology and Drug Design

JULY 27, 2023

Abstract The small molecule, isatin, is a well-known reversible inhibitor of the monoamine oxidase (MAO) enzymes with IC 50 values of 12.3 This study investigated the SARs of MAO inhibition by isatin analogues and discovered five compounds with IC 50  < 1 μM. μM for MAO-A and MAO-B, respectively.

Small Molecule 100

Small Molecule Treatment Disease Drugs 100

PPD

JUNE 27, 2024

In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on small molecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.

Treatment 52

Treatment Clinical Trials Clinical Research Small Molecule 52

PerkinElmer

JANUARY 21, 2021

When a research team at the National Center for Advancing Translational Sciences (NCATS), an institute within the NIH, was tasked to help find a possible therapeutic, they decided on a drug repurposing strategy. The post Repurpose, Reuse, Rediscover Drugs for COVID-19 Treatments first appeared on PerkinElmer Blog.

Treatment 52

Treatment Small Molecule Drugs Virus 52

The Pharma Data

JULY 12, 2021

Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrier InnoCare to receive a $125 million upfront payment and is eligible to receive potential development and commercial milestone payments. Head of Research and Development at Biogen.

Small Molecule 52

Small Molecule Treatment Disease Production 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. Acta Cryst. Acta Cryst. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

PerkinElmer

NOVEMBER 9, 2022

Immunotherapy has revolutionized cancer treatment and proved to be pivotal in the field of oncological research. Recent efforts have focused on the development of small-molecule inhibitors as an alternative approach to therapeutically target PD-1 or PD-L1.

Small Molecule 52

Small Molecule Research Immune Response FDA Approval 52

PPD

NOVEMBER 11, 2024

However, getting essential treatments to patients quickly and safely requires more than just technological innovation. A global network with local expertise To ensure the delivery of treatments to patients worldwide, biotech and biopharma companies also need partners that can provide comprehensive solutions from a geographic perspective.

Drug Development 97

Drug Development Clinical Trials Drugs Small Molecule 97

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. The Company has created a covid19@soseiheptares.com contact address for companies and researchers who would like to discuss possible collaborations.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. In addition, we have advanced zavegepant, our intra-nasal CGRP receptor antagonist, successfully through its first pivotal trial, also for the acute treatment of migraine. TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

NOVEMBER 29, 2020

Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the treatment of debilitating protein misfolding disorders such as Parkinson’s disease.”.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 15 Figure 1: A schematic illustrating a bispecific antibody-drug conjugate (ADC).

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

Drug Target Review

AUGUST 25, 2023

What makes RRx-001 a first-in-class hypoxia-activated therapeutic, and how does its dual mechanism of action differ from traditional cancer treatments? Most, if not all, traditional cancer treatments are single minded. Journal of Cancer Research and Clinical Oncology. References Oronsky B, Scribner C, Aggarwal R, Cabrales P.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. SLV213 is a novel, orally available, small molecule antiviral drug candidate that inhibits human host cell cysteine proteases to block viral entry.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52